网站首页期刊介绍通知公告编 委 会投稿须知电子期刊广告合作联系我们
最新消息:
肠道益生菌制剂对肝硬化失代偿期患者肠黏膜的保护作用
作者:罗欣  
单位:广西柳钢集团公司医院
关键词:益生菌 肝硬化失代偿期 肠黏膜 
分类号:
出版年·卷·期(页码):2014·42·第四期(407-410)
摘要:

目的:探讨肠道益生菌制剂对肝硬化失代偿期患者肠黏膜的保护作用。方法:收集肝硬化失代偿期患者82例,随机分为观察组和对照组,各组41例,另设正常组40例,对照组采用常规治疗方法,观察组在对照组基础上合用肠道益生菌制剂治疗,正常组不做任何处理,比较三组患者治疗前后肠道通透性、血内毒素水平、肠道菌群变化情况。结果:治疗前,对照组和观察组LAC、LAC/MAN、ETX均较正常组升高,MAN较正常组降低(P<0.05),观察组、对照组患者肠道内双歧杆菌、类杆菌、乳杆菌较正常组明显降低,梭菌、肠杆菌、酵母样真菌则明显升高(P<0.05);治疗后,观察组LAC、LAC/MAN、ETX均较对照组降低明显(P<0.05),观察组双歧杆菌、类杆菌、乳杆菌、肠球菌明显高于对照组,肠杆菌、酵母样真菌明显低于对照组(P<0.05)。结论:肠道益生菌制剂可明显改善肝硬化失代偿期患者的肠道通透性,减少ETX的生成,同时改善肠道菌群的微生态平衡,修复肠粘膜屏障,进而改善了患者的预后,值得临床推广应用

Objective: To investigate protective effect of intestinal mucosa of patients with loss compensatory stage of cirrhosis treated with Intestinal probiotics. Method: 82 cases of patient with loss compensatory stage of cirrhosis were selected and randomly divided into observation group and control group, in each group there were 41 cases, another normal group there 40 cases was set,control group were treated with conventional therapy, observation group were treated with intestinal probiotics on the base of control group, normal group were without any treatment,the intestinal permeability, ETX level,intestinal flora changes among three groups before and after treatment were compared .Result: before treatment, the LAC, LAC/MAN, ETX in observation group and control group were higher than the normal group,the MAN was lower than that of normal group (P<0.05),the intestinal Bifidobacterium, Lactobacillus, Bacteroides in observation group and control group were significantly lower than that in normal group, the clostridium, enterobacter, yeast-like fungi were increased markedly (P<0.05); after treatment,the LAC, LAC/MAN, ETX were lower than those in control group (P<0.05), the Bifidobacterium, Lactobacillus, Bacteroides, Enterococcus in observation group was significantly higher than those of control group,the intestinal bacteria, yeasts was significantly lower than those in control group (P<0.05). Conclusion: intestinal probiotics can significantly improve the intestinal permeability of patients with loss compensatory stage of cirrhosis,reduce production of ETX, at the same time, improve intestinal flora microecology balance, repair intestinal mucosa barrier, and then improve patient’s prognosis, it is worthy of clinical application.

参考文献:
服务与反馈:
文章下载】【发表评论】【查看评论】【加入收藏
提示:您还未登录,请登录!点此登录
您是第 760354 位访问者


 ©《现代医学》编辑部
联系电话:025-83272481;83272479
电子邮件: xdyx@pub.seu.edu.cn

苏ICP备09058541